The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
The drugs don’t work? antidepressants and the current and future pharmacological management of depression
Open accessAbstract
Depression is a potentially life-threatening disorder affecting millions of people across the globe. It is a huge burden to both the individual and society, costing over £9 billion in 2000 alone: the World Health Organisation (WHO) cited it as the third leading cause of global disability in 2004 (first in the developed world), and project it will be the leading cause by 2030. The serendipitous discovery of antidepressants has revolutionized both our understanding and management of depression: however, their efficacy in the treatment of depression has long been debated and recently been brought very much into the public limelight by a controversial publication by Kirsch, in which the role of placebo response in antidepressant efficacy trials is highlighted. Whilst antidepressants offer benefits in both the short and long term, important problems persist such as intolerability, delayed therapeutic onset, limited efficacy in milder depression and the existence of treatment-resistant depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene
Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., et al. (2003) · Science · doi:10.1126/science.1083968 · Cited by 8,120 · cited 1×
“This fits in with genetic research from Caspi and colleagues that individuals heterozygous or homozygous for the short allele are more susceptible to depression following stressful events [Caspi et al. 2003].”
BackgroundRequirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 4×
“…in which the time lag is attributed to antidepressants causing altering intracellular enzymes (for example, adenylyl cyclase, cyclic adenosine monophosphate [cAMP] and protein kinase A) which activates expression of the neuroprotective BDNF [Malberg and Duman, 2003; Santarelli et al. 2003].”
BackgroundInfluentialKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 2×
“com 181 with higher response rates (50% reduction in Hamilton Depression Rating Scale [HDRS] scores) and improved remission rates (HDRS score of less than 8) [Davis et al. 1993; Walsh et al. 2002; Arroll et al. 2005].”
BackgroundRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“Geddes and colleagues report a 70% reduction in risk of relapse compared with placebo, which persisted up to 36 months after recovery [Geddes et al. 2003].”
BackgroundMalberg, J. E., & Duman, R. S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300234 · Cited by 815
Treatment and prevention of depression
Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002) · Psychological Science in the Public Interest · doi:10.1111/1529-1006.00008 · Cited by 511
Cited by
Biological, Psychological, and Social Determinants of Depression: A Review of Recent Literature
Remes, O., Mendes, J. F., & Templeton, P. (2021) · Brain Sciences · doi:10.3390/brainsci11121633 · Cited by 482
Visual Impairment and Mental Health: Unmet Needs and Treatment Options
Demmin, D. L., & Silverstein, S. M. (2020) · Clinical Ophthalmology · doi:10.2147/opth.s258783 · Cited by 290
High anxiety trait: A vulnerable phenotype for stress-induced depression
Weger, M., & Sandi, C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.01.012 · Cited by 270
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Prado, C. E., Watt, S., & Crowe, S. F. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9369-5 · Cited by 188
Tolahunase, M. R., Sagar, R., Faiq, M., & Dada, R. (2018) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-170810 · Cited by 167
An adaptationist perspective on the etiology of depression
Durisko, Z., Mulsant, B. H., & Andrews, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.032 · Cited by 140
Taliaz, D., Spinrad, A., Barzilay, R., Barnett-Itzhaki, Z., Averbuch, D., Teltsh, O., Schurr, R., Darki-Morag, S., & Lerer, B. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01488-3 · Cited by 93
Clinical research challenges posed by difficult-to-treat depression.
Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291721004943 · Cited by 89
“…clinical utility of anti-depressant medications and psychotherapies in depressive and related mood disorders have been lowered, particularly for individuals who have a history of nonresponse to several standard forms of therapy (Cuijpers, Karyotaki, Reijnders, & Ebert, 2019; Penn & Tracy, 2012).”
Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
dos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986422 · Cited by 55
Cole, E., Gulser, M., Stimpson, K., Bentzley, B., Hawkins, J., Xiao, X., Schatzberg, A., Sudheimer, K., & Williams, N. (2019) · Brain Stimulation · doi:10.1016/j.brs.2018.12.299 · Cited by 31
Grammatopoulos, D. K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.013 · Cited by 26
Serotonin is a common thread linking different classes of antidepressants
Witt, C. E., Mena, S., Holmes, J., Hersey, M., Buchanan, A. M., Parke, B., Saylor, R., Honan, L. E., Berger, S. N., Lumbreras, S., et al. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.10.009 · Cited by 18
Study on the comorbid mechanisms of sarcopenia and late-life depression
Wu, J., Tang, J., Huang, D., Wang, Y., Zhou, E., Ru, Q., Xu, G., Chen, L., & Wu, Y. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115538 · Cited by 12
“Additionally, studies have found that depressed individuals often have low plasma levels of tryptophan (Trp), which is a precursor to serotonin[90], Depletion of Trp significantly impacts 5-HT synthesis in the brain, further contributing to depressive symptoms.”
Maneenet, J., Monthakantirat, O., Daodee, S., Boonyarat, C., Chotritthirong, Y., Kwankhao, P., Pitiporn, S., Awale, S., & Chulikhit, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14070659 · Cited by 10
Metadata
- Authors
- Penn, E., & Tracy, D. K.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-04-30
- Volume
- 2
- Issue
- 5
- Pages
- 179-188
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- OpenAlex
- W2105571318
- Cited by
- 200
- References
- 21
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.